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Reproductive health among cancer survivors is an important quality of life issue. Certain
cancer therapies have known fertility risks. There is an existing cohort of adolescents and
young adults (AYA) cancer survivors that, seen less frequently in clinical care settings than
active patients, are likely not having discussions of fertility and other reproductive health
issues. A survivor or healthcare provider can easily assume that the window of opportunity
for fertility preservation has passed, however emerging research has shown this may not
be the case. Recent data demonstrates a close relationship between fertility and other late
effects to conclude that ongoing assessment during survivorship is warranted. Some fer-
tility preservation procedures have also been shown to mitigate common late effects.This
review explores the link between late effects from treatment and common comorbidities
from infertility, which may exacerbate these late effects. This review also highlights the
relevance of fertility discussions in the AYA survivorship population.
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INTRODUCTION
Reproductive potential and other reproductive health concerns
among cancer survivors is an important quality of life issue. Cer-
tain cancer therapies, particularly alkylating chemotherapy agents
and radiation, have known fertility risks. Fertility issues within
oncology have ignited a robust research focus that explores phys-
iologic and psychological late effects, advancing technologies that
reduce the risk of becoming infertile in the future, and broader
reproductive health concerns such as appropriate contraception
and the HPV vaccine (1–4). Sustained infertility may develop in
50–95% of cancer survivors, largely in patients who have under-
gone high-dose chemotherapeutic conditioning regimens for bone
marrow transplants (5–7). However, there are fertility preserva-
tion options available to adolescents and young adults (AYA) at
multiple time points during the course of cancer care. The most
efficacious time to pursue such options is before starting treat-
ment, though the perceived need to start treatment immediately
often hinders these options.
There are heterogeneous reports exploring the rates of discus-
sion of fertility. Ranging from 34 to 70% (8–11), whether or not
a patient receives information is based on a variety of factors,
many of which are outside the individual’s. It is clear however, that
the majority of cancer survivors did not receive information on
fertility prior to treatment.
Adolescents and young adults cancer survivors have distinct
developmental needs. While many adolescents without a history of
cancer spend these formative years affirming their unique identity,
survivors are on a journey toward “normal,” as they have experi-
enced significant disruption in identity formation (12). Engaging
in social and romantic relationships is a healthy developmental
milestone of any AYA, wherein sexuality is explored and future
plans to marry and have children are considered (13).
With attention to fertility gaining more attention in pediatric
oncology settings, discussions are improving (11). That is signif-
icant progress for newly diagnosed patients, and we anticipate
this trend will continue. However, there is an existing cohort of
AYA cancer survivors that, seen less frequently in clinical care
settings than active patients, are likely not having discussions
of fertility and other reproductive health issues. The Children’s
Oncology Group (COG) has issued long-term follow-up guide-
lines that detail the management of pertinent late effects which
include referrals to reproductive specialists (14), but lack speci-
fying what fertility options may be valuable during survivorship.
COG also recently assembled task forces to develop guidelines for
male and female survivors and reproductive health but do not
address how the effects of infertility may compound existing late
effects (15–17).
This AYA survivorship cohort is growing (16) but survival
does not come without a cost. AYA cancer survivors have been
found to have poorer physical and psychosocial outcomes than
their healthy peers, thus warranting close monitoring. AYA can-
cer patients diagnosed before the American Academy of Pedi-
atrics (18) and the American Society of Clinical Oncology (19)
published guidelines on fertility preservation in pediatric can-
cer patients in 2008 and 2006, respectively, were not likely
to receive reproductive health information prior to treatment.
Does that mean the window of opportunity to make referrals
to reproductive specialists has passed? This review explores the
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relevance of ongoing fertility discussions in the AYA survivor-
ship population due to the interrelatedness of common late
effects from treatment, and common comorbidities from infer-
tility, which may exacerbate or be concealed within these late
effects. We also discuss fertility preservation options that are avail-
able to AYAs post-treatment that may also treat some specific late
effects.
THE IMPORTANCE OF REPRODUCTIVE HEALTH MONITORING
There are likely misconceptions regarding AYA cancer survivors’
quality of life concerns. There is an overshadowing focus on sur-
vivors’ disease status and the assumption that cancer survivors are
less interested in sex and reproduction than their healthy peers. In
reality, research indicates adolescents with a chronic illness are at
least as sexually active as their healthy counterparts (20, 21). The
sentiments of the medical community, combined with cultural
taboos of AYA sexuality present barriers to conveying medically
imperative information to survivors regarding fertility, sex educa-
tion, contraception, and risks of sexually transmitted infections
(STIs). There is a distinct interrelatedness among existing late
effects experienced during survivorship and fertility preservation
outcomes after treatment (Figure 1). Fertility preservation options
that may mitigate treatment-induced late effects are highlighted
later in this review.
PHYSIOLOGICAL EFFECTS OF INFERTILITY
There are unique relationships among infertility and the late effects
of cardiotoxicity, bone health, and other endocrine disorders. It
is important for healthcare providers (HCP) to be aware of the
potential for infertility to exacerbate these late effects. At the same
time, HCP must also be aware of the risk for infertility symptoms
to go untreated due to a focus on other common physiological late
effects. We discuss late effects that HCP routinely assess, and the
similarity of these symptoms within infertile persons that may go
overlooked.
CARDIOTOXICITY
It is well documented that survivors are at risk for cardiovascu-
lar disease and mortality due to treatment alone (22–24). Females
have an increased susceptibility to cardiotoxicities during survivor-
ship (25). Radiation therapy and certain chemotherapeutic agents
utilized in the treatment of pediatric cancer are frequently linked to
cardiac dysfunction in survivors (26). Long-term effects of radia-
tion on the cardiovascular system can include premature coronary
artery disease, constrictive pericarditis, and pericardial effusions
(27). Further, the chemotherapeutic classes of Anthracyclines are
agents generally associated with cardiac sequelae such as acute-
arrhythmias, hypotension, and a decrease in cardiac function,
which can lead to congestive heart failure (28).
Infertility may aggravate these existing cardiovascular impair-
ments. Females who experience premature ovarian failure (POF)
as a result of treatment are at risk of cardiovascular disease due
to the early loss of estrogen (29, 30). Estrogen has been shown to
maintain healthy blood pressure and plasma fibrinogen levels, a
risk factor of cardiovascular disease. Estrogen prevents white blood
cells from adhering to the lining of blood vessels, therefore patients
with normal estrogen levels have a reduced risk of developing ath-
erosclerotic plaque (31, 32). Among men, testosterone serves as
a cardioprotective hormone as well, and a significant decrease
in testosterone, as is often experienced following chemotherapy,
places patients at risk for cardiovascular disease (33). Low testos-
terone may also contribute to coronary artery constriction (34),
which may increase survivors’ risk of atherosclerotic disease and
stroke (35). Infertility can compound the cardiovascular risk exist-
ing from treatment, therefore there is an increased need for special-
ized attention to manage survivors and could necessitate changes
in the interventions prescribed.
BONE HEALTH
Bone health may also be affected by both infertility and cancer
treatment, and should be regularly assessed at follow-up visits.
Reduction in bone health quality from treatment can occur in a
variety of ways. Many commonly utilized chemotherapies, such
as corticosteroids, antimetabolites, anthracyclines, and alkylating
agents have been shown to adversely impact bone mineral density
(BMD) through creating an imbalance in bone metabolism with
increased bone resorption and decreased bone formation (36–38).
These agents are directly toxic to osteoblast maturation, inhibit
bone promoting growth factors, and promote osteoclast activity.
The question of bone health is particularly problematic in a pedi-
atric patient population as an individual’s peak bone mass for life is
attained in late adolescence (39). The chemotherapy necessary for
cure therefore coincides and interferes with this vital time period
for bone formation with lifelong implications.
Survivorship Fertility
Late Effects
Cardiotoxicities
Endocrinopathy
Psychosocial
Fertility
Preservation
FIGURE 1 | Relationship of fertility and late effects in survivorship.
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Gonads in both males and females secrete hormones that facil-
itate bone metabolism (40). There is a clear association between
skeletal health and gonadal function in survivors (41) that high-
lights the need to address reproductive health in this population to
maximize potential bone density even long after therapy is com-
pleted. Recent research has examined the relationship between
skeletal health and ovarian function, which exhibits a cyclical asso-
ciation. Females with POF often have low BMD increasing the risk
of fracture and delayed healing (42, 43). Specifically, patients with
POF caused by chemotherapy present with rapid bone mineral loss
(44). The cyclical relationship is exhibited in the exacerbation of
vasomotor symptoms such as hot flashes and night sweats related
to infertility by low BMD (45). Because estrogen helps protect
against the destruction of osteoblasts, the decrease of estrogen due
to infertility has potential to cause significant bone health issues
for survivors. The rapid loss of estrogen in women experiencing
POF, which acts as a transition period to menopause, accelerates
the rate of BMD loss, and patients who have poor bone health due
to treatment-induced infertility may experience further deterio-
ration. This places even young survivors at an increased risk for
osteopenia and osteoporosis.
In males, there is a unique, reciprocal relationship between bone
health and fertility. Evidence for this can be found in adults with
liver cancer; in those with impaired gonadal function and osteo-
porosis, liver transplantation was found to have restorative action
on both gonad function and bone health (46). Conversely, low
BMD can induce infertility in males. Osteocalcin promotes pro-
duction of testosterone in the testes, and low osteocalcin therefore
impacts testosterone level as well (47). Assessment of fertility func-
tion by providers during visits is therefore one key determinant of
poor bone health. Similarly, as BMD is often routinely monitored
in AYA survivors, those with poor bone health, providers should
also routinely assess fertility and testosterone levels as risk factors
for infertility. The strong association between fertility and bone
health in males and females supports the current recommenda-
tions for, providers to assess gonadal function during follow-up
visits.
ENDOCRINE LATE EFFECTS
Perhaps the strongest relationship warranting close assessment is
that of infertility and endocrine late effects. Up to 50% of survivors
have reported effects such as hypopituitarism, precocious puberty,
and adrenal insufficiency (48). Endocrine disturbances are largely
attributed to the location of the cancer, the class and dose of
chemotherapy, the amount, location and type of radiation, and the
length and time from treatment, similarly to the risk of infertility.
Survivors treated at a young age or with radiation to the head, neck,
or spine are at the greatest risk for developing endocrinopathies
(49). In fact, up to 90% of childhood brain tumor survivors
have been reported to have some evidence of growth hormone
deficiency at a median of 4 years post-treatment (50). Thyroid defi-
ciency may cause fatigue, weight gain, and depressed mood which
mimic frequent symptoms of infertility. Early recognition and
treatment of these conditions is extremely important since they
can have a significant influence on optimal growth and develop-
ment, cognition and progression of pubertal maturity, but should
not be assessed in isolation from fertility status. Endocrine late
effects include those of reproductive health. Cancer treatment
such as radiation and alkylating agents like cyclophosphamide
and procarbazine used for solid tumors may damage endocrine
organs that have a high cell division rated, preventing the function
of gonadotropin-releasing hormones (51). The affected pituitary
can fail to produce hormones that stimulate testosterone and
estrogen production (52). Impaired hormonal metabolism affects
gonadal function and the ability to produce sperm and release
eggs. Further, treatment-induced hyperprolactinemia can affect
the reproductive system in males and females. In females, high
prolactin also causes galactorrhea (breast milk production in a
non-breast feeding person) and absent or irregular menses (53). In
males, hyperprolactinemia can trigger galactorrhea and low testos-
terone resulting in decreased libido (54). Hyperprolactinemia can
be caused by radiation to the hypothalamus gland (55).
In females, chemotherapy and radiation have varying risks on
the reproductive organs as well as the endocrine system that reg-
ulates hormones within these organs. Females are particularly at
risk of infertility due to cancer treatment as females are born with
a finite number of non-replicating oocytes. Furthermore, luteiniz-
ing hormones stimulate theca cells to produce a steroid hormone
that is converted to sex hormones in the granulosa cell which is
stimulated by follicular stimulating hormone (FSH) (56). This
process mature oocytes. Damage to theca and granulose cells from
alkylating chemotherapeutic agents can prevent this maturation
process and cause premature menopause (57). It is difficult to
predict when POF will occur, as some reports have shown this
immediately after administration of treatment, while others have
reported a significant delay (15, 58). Endocrine function not only
plays a role in maintaining ovarian function, but also in predicting
it. Assessing direct hormone products of the ovary such as FSH,
Inhibin B, and anti-Mullerian hormone (AMH), can show how
the ovarian is functioning. Measuring AMH is useful in the detec-
tion of early growing follicles, which may be a better predictor of
ovarian reserve (59).
Men may experience comparable menopausal symptoms dur-
ing andropause such as osteoporosis and sexual dysfunction as
a result of a dramatic decrease in testosterone (60). Andropause
occurs naturally among aging males, and technology can help pre-
dict if a male is at risk for premature andropause. However, it is dif-
ficult to predict when an AYA male will experience these symptoms
after cancer therapy. Screening tests such as the Androgen Defi-
ciency in Aging Males (ADAM) self-report questionnaire, as well
as evaluating testosterone serum levels are valuable in monitoring
the likelihood of andropause (61). It is difficult to assess how
long after the completion of treatment an AYA will enter per-
manent menopause/andropause, which may still occur naturally
at the anticipated time point later in life, necessitating an ongo-
ing assessment plan. Hormone therapy is the treatment for many
endocrine disorders, which may also alleviate negative symptoms
of infertility such as abnormal or painful periods in females, skin
changes, and hair growth. Conversely, treatment for infertility may
reduce the impact of endocrine disorder symptoms. The interre-
lationship among endocrine dysfunction from cancer treatment
and reproductive health issues from cancer treatment provides
evidence for examination of their combined potential to impact
AYA survivors. Knowledge and awareness of late effects along with
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clinical vigilance and early intervention is crucial for this unique
population in order to reduce the impact and morbidity of these
late effects.
PSYCHOLOGICAL EFFECTS OF INFERTILITY
Male and female cancer survivors can be burdened with emotional,
social, and psychological consequences as a result of infertility.
AYA survivors have experienced a dramatic acceleration of life’s
challenges, beginning with confronting their own mortality. Sur-
vivorship comes with a new set of complications, negotiations, and
coping skills. Adolescent cancer patients have been shown to have
long-term goals that include childbearing and parenthood, as well
as informational needs for fertility preservation (62). A diagnosis
of cancer does not derail these goals. As a result of infertility, some
survivors have reported low self-esteem, regret for not questioning
infertility risks, guilt for current partner, or fear of never finding a
partner (63).
Other barriers may prevent the assessment of reproductive
potential aside from solely physician awareness. Males may be
uniquely overlooked regarding the psychosocial effects of sur-
vivorship. Male AYA survivors have been noted to have issues with
body image and appearance, masculinity and sexuality, cynical
about planning for future parenthood, and afraid of transmitting
cancer to a partner (64). Perceptions of male stoicism and lack of
concern about appearances may prevent these issues from being
assessed due to a fear of embarrassment for both the patient and
provider. Additionally, there are financial costs associated with
assessment of and treatment for fertility preservation that are cur-
rently not always covered by health insurance. To this end, the
potential financial burden to parents and patients may also inhibit
providers from discussions.
The existing AYA survivorship cohort seen for follow-up care is
in a unique transitional period, not only the transition of patient
to survivor, but also the normative developmental transition of
adolescent to adult. Past goals are now seen as capable of becom-
ing actualized in adulthood, including goals for parenthood; an
unknown fertility status may heighten distress and anxiety (1).
Zebrack et al. found that of 32 childhood cancer survivors, the
majority placed a high value on future parenthood, however 60%
had an unknown fertility status (1). An unknown fertility status
has potential to magnify psychosocial issues arising from the can-
cer experience as well as create unique stressors as a result of the
cancer experience. For example, Halliday et al. reports that young
female survivors felt “rushed” to enter parenthood because time
spent on treatment had disrupted formative reproductive years
(65). Halliday goes on to explain feelings of “otherness” felt by
female survivors with an unknown fertility status, in that rejoin-
ing the young adult social cohort creates a sense of devalue and
divergence from the norm from those who did not experience
cancer and assume a fertile capacity (65, 66). Infertility, whether
confirmed, perceived, or questioned, invokes a variety of coping
mechanisms such as information-seeking and anticipatory grief
that can be supported and directed with appropriate psychosocial
care.
FERTILITY OPTIONS FOR SURVIVORS
Fertility can be compromised in different ways for males and
females depending on the initial disease site, stage, age of patient,
therapeutic treatment regimen, and condition of the patient. Alky-
lating agents within some chemotherapies do not target specific
cells, and therefore affect all cells, especially those that divide
rapidly such as cancer cells in the bone marrow. Other cellular
activity can be impacted such as also oogoniums in pre-pubertal
females, primary oocytes, and sperm cells, as well as theca and
granulose cells in ovarian follicles that mature oocytes (67–69).
Because alkylating agents have high potential to destroy these
important reproductive cells, pursuing fertility preservation prior
to treatment is most advantageous and carries the greatest like-
lihood to restore reproductive potential. HCP may believe this
damage is irreparable and unavoidable, and elect to avoid repro-
ductive health discussions during survivorship care. However,
there is evidence that pursuing fertility preservation options even
after treatment, and even after confirmed infertility, shows poten-
tial to regain reproductive function. Successful pregnancies after
ovarian tissue cryopreservation followed by transplantation have
been reported in some human studies (70–74). Gosiengfiao et al
performed a unilateral oophorectomy on a 9-year-old female who
had finished treatment for rhabdomyosarcoma, which included
alkylating agents such as cyclophosphamide. Examination of
the re-implanted tissue found viable primordial follicles despite
aggressive treatment (75). Additionally, Meirow et al reported a
live birth resulting from ovarian tissue cryopreserved after treat-
ment for Non-Hodgkin Lymphoma and confirmed ovarian failure
for 2 years in a 28-year-old survivor (72).
Male survivors who did not undergo a fertility-sparing proce-
dure before treatment also have options post-treatment if fertility
is impaired. Due to the rapid regeneration of sperm, recovery of
reproductive potential in males after treatment with non-akylating
chemotherapeutic agents is higher than with alkylating agents
(76). Naysmith et al. confirmed that fertilization could be achieved
via testicular biopsy of a male testicular cancer survivor 8 years
post-treatment, who was confirmed to be azoospermic (77). The
options for survivors who are interested in a future pregnancy are
expanding as rapidly as the science behind it. Men with confirmed
infertility years off treatment can still take advantage of testicular
sperm extraction (TESE) and Intracytoplasmic sperm injection
(ICSI) methods where minimal sperm can be used to achieve a
pregnancy (70). Physicians should take advantage of the availabil-
ity and expertise of reproductive specialists who can consult with
the patient and determine the eligibility for procedures.
OTHER BENEFITS OF FERTILITY PRESERVATION
In addition to achieving pregnancy, some fertility preservation
options may offset other late effects experienced as a result of
treatment. Recent experimental trials have examined the benefits
of re-implantation of ovarian tissue in females for purposes other
than achieving a pregnancy. Transplantation of cryopreserved
ovarian tissue has shown to be a potential method for recovery
of ovarian function (78, 79), which carries a variety of benefits
by staving off symptoms of menopause. Ovarian tissue transplan-
tation has recently been shown to restore endocrine function in
young women after cancer treatment (80, 81). Oktay et al. trans-
planted cryopreserved ovarian tissue that resulted in decreased
FSH and LH levels as well as stabilizing estradiol levels (81).
This took approximately 10 weeks after transplantation. Other
patients resumed normal menstrual cycles and hormone levels
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about 5 months after transplantation (82, 83). Males have been
shown to resume testosterone production after re-implantation of
cryopreserved testicular tissue (84). Though no study has exam-
ined testicular tissue taken after cancer treatment, some infertility
treatments such as TESE/ICSI show promise that even after treat-
ment testicular tissue may be viable and could offer endocrine and
cardiac benefits similarly to ovarian tissue transplantation.
CONCLUSION
It is important to keep up with the fast-paced technologies
of fertility treatments, as it is to stay abreast of the latest
treatment regimens. Active treatment is being re-shaped by the
push to discuss fertility preservation options prior to treat-
ment, which is a result of the needs expressed by the ever-
expanding, vocal survivorship cohort that exists today. What’s
now needed is a way to bridge these two worlds and inform
survivors that the window of opportunity for future parent-
hood, reversing POF and other late affects may not be gone.
Long-term follow-up guidelines should incorporate the benefits
of discussing fertility and fertility preservation options so that
HCP can ensure comprehensive care and long-term quality of
life.
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